Press release
Bispecific Antibody Competitive Landscape Report 2024 (Updated) | Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, and others.
Bispecific Antibody Competitive Landscape
Key Takeaways from the Bispecific Antibody Competitive Landscape Report
• DelveInsight's Bispecific Antibody report depicts a robust space with 250+ active players working to develop 300+ pipeline therapies for Bispecific Antibody treatment.
• The leading companies working in the Bispecific Antibody Competitive landscape include Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, Jiangsu Alphamab Biopharmaceuticals, Sichuan Baili Pharmaceutical, Regeneron Pharmaceuticals, Boehringer Ingelheim, and others.
• Promising Bispecific Antibody Therapies in the various stages of development include SI-B003, AK104, Bevacizumab, Paclitaxel, AK112, LY3434172, CDX-527, Etoposide, Carboplatin, and others.
• December 2023: Hoffmann-La Roche, An Open Label, Multicenter, Dose Escalation, Phase 1 & 2 Clinical Study to Evaluate Safety/Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-Tumor Activity of RO7247669, a PD1-LAG3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors.
• December 2023: Janssen Research & Development Inc. announced a study of Phase 1 clinical trials for Teclistamab (IV). The purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for Teclistamab and to characterize the safety and tolerability of Teclistamab at the RP2Ds.
Request a sample and discover the recent advances in Bispecific Antibody Drugs @ Bispecific Antibody Competitive Landscape Report- https://www.delveinsight.com/sample-request/bispecific-antibody-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
The Bispecific Antibody competitive landscape report provides an in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing, and acquisition - deal values trends. The sub-segmentation is described in the Bispecific Antibody report which provides company-company collaboration (licensing/partnering), company academic collaboration, and acquisition analysis in tabulated form.
Bispecific Antibody Overview
Immunoglobulins (antibodies [Abs]) are major protein components of the adaptive immune system, directed against foreign compounds and infectious agents. The IgG molecule consists of two light and two heavy chains connected by disulfide bonds; IgG is a monomer with a molecular weight of 146-160 kDa. Antigen-binding centers of Abs are formed by hypervariable regions of heavy and light chains. In the classical point of view, the Ab molecule contains two identical antigen-binding sites (two HL fragments) and is monospecific and bivalent.
Find out more about Bispecific Antibody Analytical Perspective: In-depth Commercial Assessment @ Bispecific Antibody Collaboration Analysis by Companies- https://www.delveinsight.com/sample-request/bispecific-antibody-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Bispecific Antibody Companies and Product Profile
• Akeso: Ivonescimab
• Zymeworks: Zanidatamab
• Roche: Glofitamab
• IGM Biosciences: Imvotamab
• MacroGenics: MGD024
Bispecific Antibody Competitive Landscape
The Bispecific Antibody competitive landscape report comprises of comparative assessment of Companies (by therapy, development stage, and technology).
Bispecific Antibody Report Assessment
• Bispecific Antibody Company Analysis
• Bispecific Antibody Therapeutic Assessment
• Bispecific Antibody Pipeline Assessment
• Inactive drugs assessment
• Bispecific Antibody Unmet Needs
Learn more about the emerging Bispecific Antibody Competitive Landscape @ Bispecific Antibody Market Drivers and Barriers, Unmet Needs- https://www.delveinsight.com/sample-request/bispecific-antibody-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Bispecific Antibody Report
• Coverage- Global
• Bispecific Antibody Therapeutics Assessment: Product Type, Stage and Product Type, Route of Administration, Molecule Type
• Bispecific Antibody Companies- Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, Jiangsu Alphamab Biopharmaceuticals, Sichuan Baili Pharmaceutical, Regeneron Pharmaceuticals, Boehringer Ingelheim, and others.
• Bispecific Antibody Therapies- SI-B003, AK104, Bevacizumab, Paclitaxel, AK112, LY3434172, CDX-527, Etoposide, Carboplatin, and others.
Dive deep into rich insights for new drugs for Bispecific Antibody Product Developmental Activities, Visit @ Bispecific Antibody Research and Development Activities- https://www.delveinsight.com/sample-request/bispecific-antibody-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Bispecific antibody: Overview
4. Bispecific Antibody -Analytical Perspective: In-depth Commercial Assessment
5. Competitive Landscape
6. Therapeutic Assessment
7. Bispecific antibody: Company and Product Profiles (Marketed Therapies)
8. Janssen
9. Amivantamab
10. Bispecific antibody: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Phase III)
12. Akeso
13. Ivonescimab
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. IGM Biosciences
17. Imvotamab
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. MacroGenics
21. MGD024
22. Drug profiles in the detailed report…..
23. Preclinical and Discovery Stage Products
24. Company Name
25. Product Name
26. Drug profiles in the detailed report…..
27. Inactive Products
28. Bispecific antibody- Unmet needs
29. Bispecific antibody - Market drivers and barriers
30. Appendix
For further information on the Bispecific Antibody Report @ Bispecific Antibody Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/bispecific-antibody-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Links-
https://www.bestadsontv.com/profile/462518/Denny-Dones
https://manybooks.net/user/denny-dones
https://topbazz.com/germanydennydones
https://wibki.com/dennydones1
https://onlineghibli.com/tavern/members.php?mode=profile&userid=12548&boardid=1
https://www.undrtone.com/germanydennydon
https://solo.to/germanydennydones
https://app.geniusu.com/users/2455075
https://forum.alidropship.com/members/germanydennydones.50354/#about
https://pantip.com/profile/7306022#topics
https://pubhtml5.com/homepage/npvs/preview
https://doodleordie.com/profile/germanydennydones
https://www.rafabasa.com/author/germanydennydones/
https://www.tabletennisdaily.com/forum/members/germanydennydones.122613/#about
https://nhattao.com/members/user6331540.6331540/
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bispecific Antibody Competitive Landscape Report 2024 (Updated) | Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, and others. here
News-ID: 3464525 • Views: …
More Releases from DelveInsight Business Research LLP
Alpha-1 Protease Inhibitor Deficiency Market Size 2032: CSL Behring, Grifols The …
DelveInsight's "Alpha-1 Protease Inhibitor Deficiency Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Alpha-1 Protease Inhibitor Deficiency, historical and forecasted epidemiology as well as the Alpha-1 Protease Inhibitor Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Alpha-1 Protease Inhibitor Deficiency Market Research Report
• The increase in Alpha-1 Protease Inhibitor Deficiency Market Size…
Amyloidosis Market Size Report 2032: Attralus Inc., Novotech Pty Limited, Criter …
DelveInsight's "Amyloidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Amyloidosis, historical and forecasted epidemiology as well as the Amyloidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Amyloidosis Market Research Report
• The increase in Amyloidosis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies…
Basal Cell Nevus Syndrome Market Size Report 2032: Latest FDA Approvals, Emergin …
DelveInsight's "Basal Cell Nevus Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Nevus Syndrome, historical and forecasted epidemiology as well as the Basal Cell Nevus Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Basal Cell Nevus Syndrome Market Research Report
• The increase in Basal Cell Nevus Syndrome Market Size…
Biliary Atresia Market Size Report 2032: Latest FDA Approvlas and Pipeline Repor …
DelveInsight's "Biliary Atresia Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the Biliary Atresia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Key Takeaways from the Biliary Atresia Market Research Report
• The increase in Biliary Atresia Market Size is a direct consequence of the increasing…
More Releases for Bispecific
Bispecific Antibodies Market Opportunity Analysis, 2018-2026
Bispecific antibody (BsAb) is an artificial protein that is composed of fragments of two different monoclonal antibodies and has ability to bind to two different types of antigen. Cancer immunotherapy is the most widely explored application of bispecific antibody. Lung, breast and colon cancer are the wider applications of BsAb. Bispecific antibody simultaneously binds to a cytotoxic cell and target tumor cell and destroys it. Bispecific antibodies are emerging a…
Global Bispecific Antibody Market Research Report Forecast 2017 to 2021Global Bi …
Report Hive Market Research Released a New Research Report of 119 pages on Title " Global Bispecific Antibody Market Research Report Forecast 2017 to 2021 "with detailed Analysis, Forecast and Strategies.
The Global Bispecific Antibody Market Research Report Forecast 2017-2021 is a valuable source of insightful data for business strategists. It provides the Bispecific Antibody industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as…
Engineered Bispecific Antibodies (BsAb) Novel Approaches & Pipeline Insights, 20 …
Engineered Bispecific Antibodies (BsAb)
Wiseguyreports.Com Adds “Engineered Bispecific Antibodies (BsAb) Market -Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2022” To Its Research Database.
Get Sample Report @
https://www.wiseguyreports.com/sample-request/476535-engineered-bispecific-antibodies-bsab-novel-approaches-pipeline-insights-2016
Covered In This Report:
Summary
DelveInsight Report, “Engineered Bispecific Antibodies (BsAb) Novel Approaches & Pipeline Insights, 2016” emphasizes on the novel bispecific antibodies technologies in research and development. The report enlists company, target antigens, phase and indication…
Bispecific Antibodies Market, Company Analysis and Forecast to 2024
Bispecific Antibodies Market Overview
Bispecific antibody (BsAb) is an artificial protein that is composed of fragments of two different monoclonal antibodies and has ability to bind to two different types of antigen. Cancer immunotherapy is the most widely explored application of bispecific antibody. Lung, breast and colon cancer are the wider applications of BsAb. Bispecific antibody simultaneously binds to a cytotoxic cell and target tumor cell and destroys it. Bispecific antibodies…
Bispecific Antibodies Market - Global Industry Analysis 2024
Bispecific Antibodies Market Overview
Bispecific antibody (BsAb) is an artificial protein that is composed of fragments of two different monoclonal antibodies and has ability to bind to two different types of antigen. Cancer immunotherapy is the most widely explored application of bispecific antibody. Lung, breast and colon cancer are the wider applications of BsAb. Bispecific antibody simultaneously binds to a cytotoxic cell and target tumor cell and destroys it. Bispecific antibodies…
Bispecific Antibodies Market to Grow Globally
Bispecific Antibodies Market Overview
Bispecific antibody (BsAb) is an artificial protein that is composed of fragments of two different monoclonal antibodies and has ability to bind to two different types of antigen. Cancer immunotherapy is the most widely explored application of bispecific antibody. Lung, breast and colon cancer are the wider applications of BsAb. Bispecific antibody simultaneously binds to a cytotoxic cell and target tumor cell and destroys it. Bispecific antibodies…
